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Angiosarcomas are rare, malignant, endothelial-cell tumors of vascular origin that can arise at any body
site. They frequently metastasize to the lung, heralded by dyspnea, hemoptysis, chest pain, pneumo-
thoraces, and diffuse pulmonary hemorrhage. However, in most cases lung metastases are discovered
after the diagnosis of a primary angiosarcoma has already been established. Very rarely will an undi-
agnosed metastatic angiosarcoma present as diffuse pulmonary hemorrhage. We describe the case of a
59-year-old male who presented to hospital with dyspnea and hemoptysis. CT chest revealed rapidly
progressing nodular changes and broncho-alveolar lavage returns were progressively bloody. Open lung
wedge biopsy ultimately revealed metastatic angiosarcoma and extensive pulmonary hemorrhage. Our
case highlights the key clinical, radiological, and pathological features of this rare malignancy that
frequently metastasizes to the lung and reminds clinicians to consider it as a cause of hemoptysis and
pulmonary hemorrhage.
© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
We describe the case of a 59-year-old male who presented to
hospital with diffuse pulmonary hemorrhage caused by an undi-
agnosed metastatic angiosarcoma. We highlight the key clinical,
radiological, and pathological features of this rare malignancy that
frequently metastasizes to the lung.2. Case presentation
A 59-year-old non-smoking male of Chinese origin presented to
hospital with a one-month history of worsening dyspnea and he-
moptysis after recent travel to rural China. He denied fever or other
constitutional symptoms. His symptoms had persisted despite
completing two courses of antibiotics. His past medical history was
signiﬁcant for hypertension, type 2 diabetes mellitus, dyslipidemia,
and thalassemia trait.
On presentation to hospital, the patient was hypoxic on room air
and he had a low-grade fever. Physical examinationwas remarkable
only for bilateral crackles on lung auscultation. No abnormal ocular,
joint, or skin ﬁndings were noted. Blood work was remarkable only
for microcytic anemia. Anti-nuclear antibody (ANA), anti-
neutrophil cytoplasmic antibody (ANCA), and anti-glomerular
basement membrane (anti-GBM) antibody testing were negative.591; fax: þ1 (416) 340 3109.
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Ltd. This is an open access article uChest CT revealed bilateral, multifocal, nodular changes with sur-
rounding ground-glass attenuation and consolidation (Figure 1A).
Bronchoscopy with broncho-alveolar lavage (BAL) was per-
formed and the BAL returns were progressively bloody. BAL cul-
tures were negative for acid-fast bacilli, viral, bacterial, and fungal
pathogens; cytology was negative for malignant cells and
hemosiderin-laden macrophages.
The case was reviewed at the weekly Respirology-Radiology
rounds, and it was decided to send the patient for an open lung
biopsy via video-assisted thoracic surgery (VATS). Shortly after the
biopsy was performed, the patient became more hypoxic and a
repeat CT chest was performed. Compared to the CT chest just two
weeks prior, therewas signiﬁcant interval worsening of the nodular
changes and ground-glass opacities. There was no evidence of
pulmonary embolus (Figure 1B).
The biopsies revealed multiple foci of highly mitotically active
spindle cells with enlarged nuclei within the lumen of multiple
pulmonary arteries. At multiple sites these cells invaded through
the pulmonary artery and inﬁltrated the surrounding lung paren-
chyma. Extensive pulmonary hemorrhage, acute and organizing
diffuse alveolar damage, and pulmonary infarcts were also noted.
The spindle cells stained positive for CD31, CD34, and vimentin
(Figure 2). The histological features, immunohistochemical staining
pattern, intravascular nature, and multifocality of the tumor were
consistent with a metastatic angiosarcoma.
The patient was seen by Medical Oncology, but was not a
candidate for chemotherapy due to his poor clinical status and
rapid deterioration. Further imaging to identify the primarynder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Fig. 1. CT chest showing bilateral, multifocal, nodulor changes with surrounding ground-glass attenuation and consolidation (A). CT chest obtained two weeks later showing interval
worsening of the nodular changes, ground-glass attenuation, and consolidation bilaterally (B).
Fig. 2. A low-magniﬁcation photomicrograph illustrating several pulmonary vessels containing the highly mitotically active spindle cells with enlarged nuclei (A,arrows). A high-
magniﬁcation view illustrating a single branching pulmonary vessels containing the spindle cell lesion (B,arrows).
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also deferred. The patient expired twenty-two days after admis-
sion. The patient's family declined autopsy.
3. Discussion
Angiosarcomas are rare, malignant, endothelial-cell tumors of
vascular origin that represent less than 2% of all sarcomas [1].
Although theymost commonly arise in the skin, angiosarcomas can
originate at any site, including the breast, liver, bone, spleen, heart,
and lung. Patients with chronic lymphedema or a history of radi-
ation exposure are at increased risk of developing angiosarcomas.
Less common risk factors include exposure to vinyl chloride,
thorium dioxide, arsenic, and immunosuppression (post liver and
kidney transplantation) [2].
Pulmonary angiosarcomas represent metastases in the vast
majority of cases. Angiosarcomas from all sites frequently metas-
tasize via hematologic spread to the lung, heralded by dyspnea,
hemoptysis, chest pain, pneumothoraces, or diffuse pulmonary
hemorrhage [1]. However, in most cases lung metastases are
discovered after the diagnosis of a primary angiosarcoma has
already been established [3]. Very rarely will an undiagnosed
metastatic angiosarcoma present as diffuse pulmonary hemor-
rhage, as in the case of our patient [3e10]. In these rare cases, the
occult primary angiosarcoma is usually not identiﬁed ante-mortem
but is most often found to be in the right atrium on autopsy [3].
There are no histological features of the pulmonary metastases that
may portend the primary site [11].
As demonstrated in our patient's CT, key radiographic features of
a metastatic angiosarcoma in the lung can include multiple bilat-
eral, solid nodules, ground-glass opacities representing pulmonaryhemorrhage, and interlobular septal thickening indicating lym-
phangitic spread. Metastases have also been reported as multiple
thin-walled cysts, or as a mixed pattern of solid nodules and thin-
walled cysts [12].
Exceedingly rare cases of primary pulmonary angiosarcomas
have been reported. Not surprisingly, primary pulmonary angio-
sarcomas present very similarly to metastatic angiosarcomas in the
lung, with dyspnea and hemoptysis being themost commonly cited
symptoms [13]. On chest CT, a primary pulmonary angiosarcoma
appears as either a solitary mass or multiple nodules in cases of
multifocal growth [14]. If the tumor invades the pleural space,
pleural effusions or pneumothoraces can be seen [13]. Differenti-
ating a primary pulmonary angiosarcoma from metastases can be
challenging, especially in cases of widespread organ involvement.
As primary pulmonary angiosarcomas are typically characterized
by more insidious growth [14], we felt that the extremely rapid
progression of our patient's disease as captured with CT imaging
was more in keeping with a metastatic angiosarcoma.
As demonstrated in this case, patients with metastatic angio-
sarcomas usually deteriorate quickly; the average survival from
time of diagnosis is 9 months [1]. Palliative chemotherapy is the
mainstay of treatment for metastatic angiosarcomas, although
current recommendations are based on limited evidence from
small retrospective or phase 2 studies [15]. Doxorubicin-based
regimens have been shown to yield progression-free survival of
3.7e5.4 months in patients with unresectable angiosarcomas [16],
and are considered ﬁrst-line treatment [15]. Speciﬁcally, doxoru-
bicin plus ifosfamide is often used as this combination was shown
to increase progression-free survival by an average of 1.7 months
compared to doxorubicin alone [16]. In 2008, a phase 2 study
showed that weekly administration of paclitaxel achieved a
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in patients with metastatic or unresectable angiosarcomas [17].
Two retrospective case series have also indicated that gemcitabine,
with or without the addition of docetaxel, may confer a clinical
response in patients with metastatic angiosarcomas [18,19]. As
such, the 2012 European Society for Medical Oncology Clinical
Practice Guidelines recommend a doxorubicin-based regimen for
metastatic angiosarcomas, but consider taxanes or gemcitabine
(with or without docetaxel) to be acceptable alternatives [20].
Molecular targeted therapies have recently come into light as
potentially promising treatment options for metastatic angio-
sarcomas. In two phase 2 studies, the tyrosine kinase inhibitors
sorafenib and imatinib yielded progression-free survival of 3.8 and
2.76 months, respectively, in patients with metastatic angiosarco-
mas [21,22]. Very recently, a phase 2 study demonstrated that
bevacizumab, a monoclonal antibody to circulating vascular
endothelial growth factor (VEGF), achieves a median progression-
free survival of 12 weeks in patients with metastatic or locally
advanced angiosarcomas [23].
4. Conclusion
As our case illustrates, metastatic angiosarcomas in the lung can
present with dyspnea, hemoptysis, chest pain, pneumothoraces, or
diffuse pulmonary hemorrhage [1]. Angiosarcomas most
commonly arise in the skin, breast, liver, bone, spleen, and heart.
The lung is the most frequent site of metastatic spread but is rarely
the site of the primary tumor [2]. Chest CT may reveal multiple
bilateral, solid nodules with ground-glass opacities, multiple thin-
walled cysts, or a mixed pattern of solid nodules and thin-walled
cysts [12]. The prognosis of metastatic angiosarcoma averages 9
months [1]. Palliative chemotherapy using doxorubicin, taxanes, or
gemcitabine (with or without docetaxel) is the treatment of choice
[20]. Further phase 3 studies are needed to determine the role of
molecular targeted therapies in the management of patients with
metastatic angiosarcomas in the future.
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